Arcus Biosciences (RCUS) EBT Margin Growth (3y) (2020 - 2026)
Powered by 
Analysis
Arcus Biosciences (RCUS) EBT Margin Growth (3y) (2020 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.51 Bn | 130.66 Bn | 2.84 Bn | -484.00 |
| 2 | Regeneron Pharmaceuticals | 85.24 Bn | 77.25 Bn | 3.93 Bn | 132.00 |
| 3 | Argenx Se | 63.46 Bn | 58.28 Bn | 1.37 Bn | 6,691.00 |
| 4 | Moderna | 57.89 Bn | 52.75 Bn | 52.00 Mn | -2,054.00 |
| 5 | Revolution Medicines | 44.02 Bn | 44.02 Bn | - | - |
| 6 | BeOne Medicines | 39.95 Bn | 34.85 Bn | 1.53 Bn | 8,006.00 |
| 7 | Alnylam Pharmaceuticals | 35.49 Bn | 32.19 Bn | 992.69 Mn | 9,980.00 |
| 8 | Royalty Pharma | 28.43 Bn | 27.59 Bn | - | -5,319.00 |
| 9 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 31,363.00 |
| 10 | Arcus Biosciences | 3.73 Bn | 3.03 Bn | - | 3,322.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 3,322.00 |
| Mar 31, 2026 | -44,094.00 |
| Dec 31, 2025 | -12,415.00 |
| Sep 30, 2025 | -32,226.00 |
| Mar 31, 2025 | -2,778.00 |
| Dec 31, 2024 | -43,708.00 |
| Sep 30, 2024 | 63,251.00 |
| Jun 30, 2024 | 56,452.00 |
| Mar 31, 2024 | 76,453.00 |
| Dec 31, 2023 | -2,336.00 |
| Sep 30, 2023 | -21,845.00 |
| Jun 30, 2023 | 232,048.00 |
| Mar 31, 2023 | 127,389.00 |
| Dec 31, 2022 | -2,682.00 |
| Sep 30, 2022 | 105,989.00 |
| Jun 30, 2022 | 133,345.00 |
| Mar 31, 2022 | 61,286.00 |
| Dec 31, 2021 | 84,585.00 |
| Sep 30, 2021 | -57,654.00 |
| Jun 30, 2021 | 36,590.00 |